Please use this identifier to cite or link to this item: https://dora.health.qld.gov.au/qldresearchjspui/handle/1/185
Title: A trial of extending hemodialysis hours and quality of life
Authors: Gallagher, M. P.
Eris, J. M.
Lin, H.
Chan, C. T.
Monaghan, H.
Grieve, S. M.
Puranik, R.
Perkovic, V.
Cass, A.
Zhang, L.
Xu, J.
Jardine, M. J.
Lo, S.
Gray, N. A. 
De Zoysa, J. R.
Howard, K.
Zuo, L.
Issue Date: 2017
Source: 28, (6), 2017, p. 1898-1911
Pages: 1898-1911
Journal: Journal of the American Society of Nephrology
Abstract: The relationship between increased hemodialysis hours and patient outcomes remains unclear. We randomized (1:1) 200 adult recipients of standard maintenance hemodialysis from in-center and home-based hemodialysis programs to extendedweekly ($24 hours) or standard (target 12-15 hours, maximum18 hours) hemodialysis hours for 12 months. The primary outcome was change in quality of life from baseline assessed by the EuroQol 5 dimension instrument (3 level) (EQ-5D). Secondary outcomes included medication usage, clinical laboratory values, vascular access events, and change in left ventricularmass index. At 12months, median weekly hemodialysis hours were 24.0 (interquartile range, 23.6-24.0) and 12.0 (interquartile range, 12.0-16.0) in the extended and standard groups, respectively. Change in EQ-5D score at study end did not differ between groups (mean difference, 0.04 [95% confidence interval, 20.03 to 0.11]; P=0.29). Extended hours were associated with lower phosphate and potassium levels and higher hemoglobin levels. Blood pressure (BP) did not differ between groups at study end. Extended hourswere associatedwith fewer BP-lowering agents and phosphate-bindingmedications, but were not associated with erythropoietin dosing. In a substudy with 95 patients,wedetected no differencebetween groups in left ventricularmass index (meandifference,26.0 [95%confidenceinterval,214.8 to 2.7]g/m2;P=0.18).Fivedeaths occurred in the extended group and two in the standard group (P=0.44); two participants in each group withdrew consent. Similar numbers of patients experienced vascular access events in the twogroups. Thus, extendingweekly hemodialysis hours did not alter overall EQ-5D quality of life score, but was associated with improvement in some laboratory parameters and reductions in medication burden. (Clinicaltrials.gov identifier: NCT00649298).L617069886
DOI: 10.1681/ASN.2015111225
Resources: /search/results?subaction=viewrecord&from=export&id=L617069886http://dx.doi.org/10.1681/ASN.2015111225
Keywords: NCT00649298antianemic agent;hemoglobin;phosphate;potassium;adult;article;clinical laboratory;controlled study;diastolic blood pressure;female;heart left ventricle mass;hemodialysis;hemoglobin blood level;human;major clinical study;male;middle aged;outcome assessment;personal experience;phosphate blood level;potassium blood level;priority journal;prospective study;quality of life;quality of life assessment;randomized controlled trial;systolic blood pressure;vascular access
Type: Article
Appears in Sites:Sunshine Coast HHS Publications

Show full item record

Page view(s)

138
checked on Mar 13, 2025

Google ScholarTM

Check

Altmetric


Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.